[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy]

Gan To Kagaku Ryoho. 2013 May;40(5):623-5.
[Article in Japanese]

Abstract

A 59-year-old woman was diagnosed with triple-negative breast cancer(TNBC)(T2N0M0)and treated with primary systemic therapy. The patient was treated with 4 courses of epirubicin and cyclophosphamide(EC)therapy every 3 weeks, followed by weekly gemcitabine-paclitaxel combination therapy. As she was judged to have achieved a partial response(PR) by ultrasound and CT examination after eight courses, she underwent partial resection of the left breast. CR was revealed by the pathological examination of the resected specimen. Gemcitabine-paclitaxel combination therapy seems to be a one of the useful preoperative chemotherapies for TNBC.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy, Needle
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Epirubicin / administration & dosage
  • Female
  • Gemcitabine
  • Humans
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Remission Induction

Substances

  • Deoxycytidine
  • Epirubicin
  • Cyclophosphamide
  • Paclitaxel
  • Gemcitabine